• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Xtandi (enzalutamide)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Xtandi (enzalutamide)

  • Profile

Profile

Contact Information

Contact: Pfizer
Website: http://www.medivation.com/

Currently Enrolling Trials

    Show More

    General Information

    Xtandi (enzalutamide) is an androgen receptor inhibitor.

    Xtandi is specifically indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

     

    Mechanism of Action

    Xtandi (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and interaction with DNA.

    Side Effects

    Adverse events associated with the use of Xtandi may include, but are not limited to, the following:

    • Asthenia/fatigue
    • Back pain
    • Diarrhea
    • Arthralgia
    • Hot flush
    • Peripheral edema
    • Musculoskeletal pain
    • Headache
    • Upper respiratory infection
    • Muscular weakness
    • Dizziness
    • Insomnia
    • Lower respiratory infection
    • Spinal cord compression and cauda equina syndrome
    • Hematuria
    • Paresthesia
    • Anxiety
    • Hypertension

    Dosing/Administration

    Xtandi is supplied as a capsule for oral administration. The recommended dose of Xtandi is 160 mg (four 40-mg capsules) administered orally once daily. Xtandi can be taken with or without food. The capsules should be swallowed whole.

    Clinical Trial Results

    FDA Approval
    The FDA approval of Xtandi was based on a randomized, placebo-controlled, multicenter trial in 1,199 subjects. The subjects were randomized to receive either Xtandi orally at a dose of 160 mg once daily (n=800) or placebo orally once daily (n=399). All subjects continued androgen deprivation therapy. The primary end point was overall survival. The prespecified interim analysis at the time of 520 events showed a statistically significant improvement in overall survival in subjects on the Xtandi arm compared to those on the placebo arm. The number of deaths was 308 (38.5 percent) in the Xtandi arm versus 212 (53.1 percent) in the placebo arm. The median survival was 18.4 months in the Xtandi arm versus 13.6 months in the placebo arm (p< 0.0001).

     

     

    Approval Date: 2012-08-01
    Company Name: Medivation
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing